Janssen registers new Phase 1 KLK2 ADC trial in prostate cancer and Phase 2b asthma study
Two new Janssen Research & Development trials were posted this week, one testing an antibody drug conjugate in advanced prostate cancer and one testing a biologic in moderate to severe asthma.
Janssen Research & Development posted two new trial registrations this week, both first posted on 2026-08-05.
- A Phase 1 trial (NCT07746713) is recruiting to test JNJ-98768111, described as an antibody drug conjugate targeting human kallikrein-2 for advanced prostate cancer1. The study plans to enroll 100 participants1 and its purpose is to find out how safe JNJ-98768111 is and the most suitable dose regimen in Part 1, and to further evaluate safety at the recommended Phase 2 dose in Part 21.
- A Phase 2b trial (NCT07746687), titled "READY-BREATHE," is not yet recruiting and will test JNJ-95597528 against placebo in adults with inadequately controlled moderate to severe asthma2. The trial plans to enroll 440 participants2, with a primary outcome of the number of asthma exacerbations through Week 482.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.